Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Boehringer Ingelheim
ClinicalTrials.gov Identifier:
NCT01004003
First received: October 12, 2009
Last updated: August 25, 2015
Last verified: August 2015

October 12, 2009
August 25, 2015
October 2009
July 2014   (final data collection date for primary outcome measure)
  • Maximum Tolerated Dose in Phase I [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    The MTD was defined as the highest dose studied for which the incidence of DLTs was 0/3 or less than 2/6 patients during the first treatment course.
  • Time to Progression (TTP) in Phase II [ Time Frame: From randomization until data cut-off (15 July 2014); Up to 1031 days ] [ Designated as safety issue: No ]
    TTP according to Response Evaluation Criteria in Solid Tumours (RECIST) 1.0 criteria based on central independent review. TTP RECIST 1.0 was defined as the time from randomisation to disease progression according to RECIST 1.0.
  • TTP (Time to Progression) for phase II [ Time Frame: Phase II (endpoints TTP, OS): minimum 4 weeks, maximum n/a ]
  • MTD for phase I [ Time Frame: Phase I (endpoint MTD): 4 weeks ]
Complete list of historical versions of study NCT01004003 on ClinicalTrials.gov Archive Site
  • Incidence of Dose Limiting Toxicity in Phase I [ Time Frame: 4 weeks ] [ Designated as safety issue: No ]
    Number of patients with dose limiting toxicity are presented
  • Objective Tumour Response by RECIST [ Time Frame: From randomization until data cut-off (15 July 2014); Up to 1031 days ] [ Designated as safety issue: No ]

    Objective RECIST 1.0 tumour response was defined as Complete Response (CR) or Partial Response (PR) and was derived from the patient's best objective RECIST 1.0 response based on central independent review.

    95% Confidence Interval presented below are computed by Clopper and Pearson method.

  • Progression Free Survival (PFS) [ Time Frame: From randomization until data cut-off (15 July 2014); Up to 1031 days ] [ Designated as safety issue: No ]
    PFS by RECIST 1.0 was defined as the duration from date of randomisation to date of progression or death, whichever occurred earlier, based on central independent review.
  • Overall Survival [ Time Frame: From randomization until data cut-off (15 July 2014); Up to 1031 days ] [ Designated as safety issue: No ]
    Overall survival was defined as the duration from date of randomisation to the date of death.
  • Drug concentration measurements (PK) [ Time Frame: minimum 4 weeks, maximum n/a ]
  • Response Rate by Response Evaluation Criteria In Solid Tumors (RECIST) [ Time Frame: minimum 4 weeks, maximum n/a ]
  • PFS (Progression Free Survival) [ Time Frame: minimum 4 weeks, maximum n/a ]
  • OS (Overall Survival) [ Time Frame: minimum 4 weeks, maximum n/a ]
  • Incidence and Intensivity adverse event (AE) [ Time Frame: minimum 4 weeks, maximum n/a ]
Not Provided
Not Provided
 
Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma
A Multicenter, Open Label, Phase I /Randomised Phase II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Oral Sorafenib for Advanced Hepatocellular Carcinoma Patients.

The study aim is to determine maximally tolerated dose (MTD) of BIBF 1120 in HCC (hepatocellular cancer) and compare efficacy of BIBF 1120 to Sorafenib in HCC patients

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Carcinoma, Hepatocellular
  • Drug: Sorafenib
  • Drug: BIBF 1120
    Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data
  • Experimental: BIBF 1120
    Phase I dose escalation and phase II using dose determined in phase I ( 200 mg BID)
    Intervention: Drug: BIBF 1120
  • Active Comparator: Sorafenib
    Intervention: Drug: Sorafenib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
125
October 2015
July 2014   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Histologically or cytologically confirmed diagnosis of hepatocellular carcinoma (HCC) not amenable tocurative surgery or loco-regional therapy (RFA, PEI, TACE)
  • Age 18 years or older
  • Eastern Cooperative Oncology Group performance score of 2 or less
  • Child-Pugh score A (score 5-6)
  • At least one measurable lesion according to RECIST 1.0 (this criterion is limited to phase II only)
  • In case a measurable lesion was previously treated by loco-regional therapy (RFA, PEI, TACE or RT) , this lesion must have to be documented as progression according to RECIST 1.0 by CT or MRI (this criterion is limited to phase II only).
  • Time interval from last local therapy (e.g. radiofrequency ablation, percutaneous ethanol injection, radiotherapy, transarterial chemoembolization) more than 4 weeks prior to start of study treatment
  • Written informed consent consistent with International Conference on Harmonisation/ Good Clinical Practice (ICH-GCP) and local legislation

Exclusion criteria:

  • Prior systemic therapy for HCC
  • Fibrolamellar hepatocellular carcinmoa (HCC)
  • Bilirubin greater than 1.5 times ULN
  • AST or ALT greater than 2 times ULN
  • Uncontrolled or refractory ascites to adequate medical therapy
  • Hepatic encephalopathy more than grade 1 according to Child-Pugh criteria
  • Prothrombin time international normalized ratio greater than 2.3, or prothrombin time more than 6 seconds prolonged than control
  • Absolute neutrophil count less than 1000 /µL
  • Platelet count less than 60000 /µL
  • Hemoglobin less than 9 g/dL
  • Serum creatinine greater than 1.5 times Upper Limit of Normal (ULN)
  • Proteinuria of Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or greater
  • Variceal bleeding within last 6 months prior to start of study treatment
  • History of major thrombotic (except portal vein thrombosis) or clinically relevant major bleeding event in the past 6 months
  • Known inherited predisposition to bleeding or thrombosis
  • Significant cardiovascular diseases (i.e. hypertension not controlled by medical therapy, blood pressure > 150/90 mmHg), unstable angina, history of myocardial infarction within the past 6 months, congestive heart failure > class II according to New York Heart Association (NYHA), serious cardiac arrhythmia, pericardial effusion)
  • Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid =< 325mg per day)
  • Major surgery within 4 weeks prior to start of study treatment
  • Treatment with other investigational drugs or participation in another clinical trial within the past four weeks before start of therapy or concomitantly with this trial (except for present trial drug)
  • Known serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the patient inappropriate for entry into the study
  • Patients who are sexually active and unwilling to use a medically acceptable method of contraception (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner for participating females, condoms for participating males) during the trial and for at least twelve months after end of active therapy
  • Current alcohol abuse or drug abuse that would limit pt ability to comply with protocol
  • Symptomatic central nervous system (CNS) metastasis
  • Life expectancy less than 12 weeks
  • Patient unable to take oral medication
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Austria,   France,   Germany,   Hungary,   Netherlands,   Poland,   Romania,   United Kingdom
Slovakia
 
NCT01004003
1199.37, 2009-011925-14
Not Provided
Boehringer Ingelheim
Boehringer Ingelheim
Not Provided
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
Boehringer Ingelheim
August 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP